ReviewJournal of nanobiotechnology2026
Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Bone and bone-related disorders remain difficult to diagnose and treat because of the dense mineralized matrix, limited vascular perfusion, complex pathological microenvironment, and insufficient site-specific accumulation of conventional agents. Liposomes, as biocompatible vesicular nanocarriers capable of loading therapeutic, genetic, and imaging cargos, have emerged as versatile platforms for bone-oriented theranostics. In contrast to previous reviews mainly focusing on general liposomal drug delivery or individual skeletal diseases, this review provides an integrated perspective on liposomal multimodal theranostics for bone disorders, emphasizing responsive delivery, diagnostic imaging, biomimetic engineering, and clinical translation. We first summarize the structural features, classification, and functional modification of liposomes, including bone-targeting ligands, stimuli-responsive release, membrane-penetrating delivery, and biomimetic designs. We then discuss their diagnostic and therapeutic applications in osteomyelitis, joint tuberculosis, rheumatoid arthritis, osteoarthritis, osteoporosis, bone defects, fracture nonunion, bone tumors, and spinal cord injury, with particular attention to radiolabeled liposomes, fluorescent probes, imaging-guided therapy, and microenvironment-responsive systems. Moreover, biomimetic liposomes, such as cell membrane-camouflaged, macrophage- or erythrocyte membrane-engineered, membrane-fusion-inspired, and organelle-delivering liposomal systems, are highlighted for their roles in immune evasion, lesion targeting, barrier penetration, and intercellular delivery. Finally, we discuss key translational challenges, including manufacturing reproducibility, stability, biosafety, immune responses, disease-model relevance, and clinical evaluation. This review aims to provide a rational framework for developing responsive and biomimetic liposomal theranostic systems for bone-related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.